Literature DB >> 11203433

Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders.

A Yermakova1, M K O'Banion.   

Abstract

Recognition of two isoforms of cyclooxygenase and reports that nonsteroidal anti-inflammatory drugs may be beneficial in devastating neurological conditions such as Alzheimer's disease have led to increased interest in cyclooxygenase function in the nervous system. In the present paper we review current data on the multiplicity of cyclooxygenase and prostaglandin mediated effects in the central nervous system (CNS). We discuss CNS cells types, including neurons, glia, and cerebrovascular elements, where cyclooxygenases-1 and -2 are expressed under normal conditions or can be induced by physiological or pathological stimuli. We also address physiological processes such as pain sensitization, CNS inflammation and fever induction that are regulated or modified by cyclooxygenase activity. Finally, we describe potential roles of cyclooxygenase in neurological diseases and rationales for nonsteroidal anti-inflammatory drug use in the treatment of neurodegenerative disorders, stroke and CNS injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11203433     DOI: 10.2174/1381612003398672

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  20 in total

Review 1.  NSAIDs in the treatment and/or prevention of neurological disorders.

Authors:  Parto S Khansari; Leanne Coyne
Journal:  Inflammopharmacology       Date:  2012-01-10       Impact factor: 4.473

Review 2.  Therapies targeting lipid peroxidation in traumatic brain injury.

Authors:  Tamil Selvan Anthonymuthu; Elizabeth Megan Kenny; Hülya Bayır
Journal:  Brain Res       Date:  2016-02-10       Impact factor: 3.252

3.  Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia.

Authors:  Bin Tang; Cristina Capitao; Brian Dean; Elizabeth A Thomas
Journal:  Psychiatry Res       Date:  2012-03-06       Impact factor: 3.222

4.  Effects of electroacupuncture intervention on expression of cyclooxygenase 2 and microglia in spinal cord in rat model of neuropathic pain.

Authors:  Li-Li Ji; Meng-Wei Guo; Xiu-Jun Ren; Dong-Yu Ge; Gen-Mao Li; Ya Tu
Journal:  Chin J Integr Med       Date:  2016-10-24       Impact factor: 1.978

Review 5.  Selenium and selenoproteins in prostanoid metabolism and immunity.

Authors:  Fenghua Qian; Sougat Misra; K Sandeep Prabhu
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-01-30       Impact factor: 8.250

6.  Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology.

Authors:  Zhongmin Xiang; Lap Ho; Shrishailam Yemul; Zhong Zhao; Wein Qing; Patrick Pompl; Kevin Kelley; Anju Dang; Weiping Qing; David Teplow; Giulio Maria Pasinetti
Journal:  Gene Expr       Date:  2002

7.  Antidepressant-like effect of celecoxib piroxicam in rat models of depression.

Authors:  Ronise M Santiago; Janaína Barbiero; Bruno J Martynhak; Suelen L Boschen; Luisa M da Silva; Maria F P Werner; Claudio Da Cunha; Roberto Andreatini; Marcelo M S Lima; Maria A B F Vital
Journal:  J Neural Transm (Vienna)       Date:  2014-01-24       Impact factor: 3.575

8.  Acetate reduces PGE2 release and modulates phospholipase and cyclooxygenase levels in neuroglia stimulated with lipopolysaccharide.

Authors:  Mahmoud L Soliman; Joyce E Ohm; Thad A Rosenberger
Journal:  Lipids       Date:  2013-05-25       Impact factor: 1.880

9.  Expression of enzymes involved in the prostanoid metabolism by cortical astrocytes after LPS-induced inflammation.

Authors:  Sonja Johann; Eric Kampmann; Bernd Denecke; Susanne Arnold; Markus Kipp; Jörg Mey; Cordian Beyer
Journal:  J Mol Neurosci       Date:  2008-01-03       Impact factor: 3.444

10.  Manganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia.

Authors:  Natalia V Malkova; Joseph J Gallagher; Collin Z Yu; Russell E Jacobs; Paul H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.